A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothers

American Journal of Epidemiology

Volumn 175, Issue 9, 2012, Pages 950-961

  Williams, Paige L ^a,b   Seage III, George R ^a,b   Van Dyke, Russell B ^c   Siberry, George K ^d   Griner, Raymond ^a   Tassiopoulos, Katherine ^a,b   Yildirim, Cenk ^a   Read, Jennifer S ^e   Huo, Yanling ^a   Hazra, Rohan ^g   Jacobson, Denise L ^a   Mofenson, Lynne M ^d   Rich, Kenneth ^f  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g NONE

Author keywords

antiretroviral; asymptotic relative efficiency; HIV exposed; infants; outcome dependent sampling; safety; surveillance

Indexed keywords

ANTIRETROVIRUS AGENT; LACTIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIMICROBIAL ACTIVITY; CHILD HEALTH; ESTIMATION METHOD; HEALTH MONITORING; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIVITY; OCCUPATIONAL EXPOSURE; TOXICITY;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FEMALE; GROWTH DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE BLOOD LEVEL; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIXED HEARING LOSS; MOTHER; NEUROTOXICITY; PERCEPTION DEAFNESS; PRESCHOOL CHILD; RANDOM SAMPLE; SAMPLE SIZE; SCHOOL CHILD; SENSITIVITY ANALYSIS; SIDE EFFECT;

ALGORITHMS; ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL INJURIES; PROSPECTIVE STUDIES; RESEARCH DESIGN;

UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84860636012     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr401     Document Type: Article

References (40)

1. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22(8):973-981.
2. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. Women and Infants' Transmission Study Group. J Acquir Immune Defic Syndr. 2002;29(5):484-494.
3. Suksomboon N, Poolsup N, Ket-aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther. 2007;32(3):293-311.
4. Public Health Service recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 1998; 47(RR-2):1-38.
5. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003;32(4):380-387.
6. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf. 2007;30(3):203-213.
7. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354(9184):1084-1089.
8. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. French Perinatal Cohort Study Group. AIDS. 2003;17(12):1769-1785.
9. Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion. 2004;4(5-6):763-777.
10. Montaner JS, Côté HC, Harris M, et al. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr. 2003; 34(suppl 1):S85-S90.
11. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr. 2000;25(3):261-268.
12. Lindegren ML, Rhodes P, Gordon L, et al. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Perinatal Safety ReviewWorking Group; State and Local Health Department HIV/AIDS Surveillance Programs. Ann N Y Acad Sci. 2000;918(1):222-235.
13. Bulterys M, Nesheim S, Abrams EJ, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women: retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Perinatal Safety Review Working Group. Ann N Y Acad Sci. 2000;918(1):212-221.
14. Dominguez K, Bertolli J, Fowler M, et al. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or 1/4 5 years of age Pediatric Spectrum of HIV Disease Project (PSD) USA. PSD Consortium; Perinatal Safety Review Working Group. Ann N Y Acad Sci, 2000 918(1) 236-246.
15. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr. 2002;30(2): 200-215.
16. Lipshultz SE, Shearer WT, Thompson B, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIVpositive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children Cohort Study). J Am Coll Cardiol. 2011;57(1):76-85.
17. Poirier MC, Divi RL, Al-Harthi L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIVinfected mothers. Women and Infants Transmission Study (WITS) Group. J Acquir Immune Defic Syndr. 2003;33(2): 175-183.
18. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007;21(8):929-938.
19. Williams PL, Van Dyke R, Eagle M, et al. Association of sitespecific and participant-specific factors with retention of children in a long-term pediatric HIV cohort study. PACTG 219C Team. Am J Epidemiol. 2008;167(11):1375-1386.
20. Glasser SP, Salas M, Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol. 2007;47(9):1074-1086.
21. Andrews E, Dombeck M. The role of scientific evidence of risks and benefits in determining risk management policies for medications. Pharmacoepidemiol Drug Saf. 2004;13(9): 599-608.
22. Brogly SB, Abzug MJ, Watts DH, et al. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J. 2010;29(8):721-727.
23. Sheon AR, Fox HE, Rich KC, et al. The Women and Infants Transmission Study (WITS) of maternal-infant HIV transmission: study design, methods and baseline data. J Womens Health. 1996;5(1):69-78.
24. Tassiopoulos K, Read JS, Brogly S, et al. Substance use in HIV-infected women during pregnancy: self-report versus meconium analysis. AIDS Behav. 2010;14(6):1269-1278.
25. Kiragga AK, Ocama P, Reynolds SJ, et al. Validation of a portable hand-held lactate analyzer for determination of blood lactate in patients on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr. 2008;49(5):564-566.
26. Griner R, Williams PL, Read JS, et al. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. Pediatric HIV-AIDS Cohort Study. AIDS Patient Care STDs. 2011;25(7):385-394.
27. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Washington, DC: Department of Health and Human Services; 2010. (http://aidsinfo. nih.gov/ContentFiles/ PerinatalGL.pdf). (Accessed April 13, 2011).
28. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2003;26(3):159-186.
29. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ. 2004;329(7456):44-47.
30. Rozich JD, Haraden CR, Resar RK. Adverse drug event trigger tool: a practical methodology for measuring medication related harm. Qual Saf Health Care. 2003;12(3):194-200.
31. Resar RK, Rozich JD, Classen D. Methodology and rationale for the measurement of harm with trigger tools. Qual Saf Health Care. 2003;12(suppl 2):ii39-ii45.
32. Resar RK, Rozich JD, Simmonds T, et al. A trigger tool to identify adverse events in the intensive care unit. Jt Comm J Qual Patient Saf. 2006;32(10):585-590.
33. Sharek PJ, Horbar JD, Mason W, et al. Adverse events in the neonatal intensive care unit: development, testing, and findings of an NICU-focused trigger tool to identify harm in North American NICUs. Pediatrics. 2006;118(4):1332-1340.
34. Dickerman MJ, Jacobs BR, Vinodrao H, et al. Recognizing hypoglycemia in children through automated adverse-event detection. Pediatrics. 2011;127(4):e1035-e1041.
35. Takata GS, Mason W, Taketomo C, et al. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals. Pediatrics. 2008;121(4):e927-e935.
36. Ferranti J, Horvath MM, Cozart H, et al. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment. Pediatrics. 2008;121(5):e1201-e1207.
37. Meyer-Massetti C, Cheng CM, Schwappach DL, et al. Systematic review of medication safety assessment methods. Am J Health Syst Pharm. 2011;68(3):227-240.
38. Zhou H, Chen J, Rissanen TH, et al. Outcome-dependent sampling: an efficient sampling and inference procedure for studies with a continuous outcome. Epidemiology. 2007;18(4): 461-468.
39. Wang X, Wu Y, Zhou H. Outcome-and auxiliary-dependent subsampling and its statistical inference. J Biopharm Stat. 2009;19(6):1132-1150.
40. Schildcrout JS, Rathouz PJ. Longitudinal studies of binary response data following case-control and stratified casecontrol sampling: design and analysis. Biometrics. 2010;66(2): 365-373.